PLAINSBORO, N.J., Oct. 7, 2010 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that it is featuring the IntegraTM Total Wrist Fusion System at the 65th Annual Meeting of the American Society for Surgery of the Hand (ASSH) on October 7-9, in Boston, Massachusetts.
The IntegraTM Total Wrist Fusion System is the latest addition to Integra's suite of solutions for wrist arthritis. Wrist fusion is a surgical procedure intended to reduce pain resulting from joint diseases, including arthritis of the wrist, particularly osteoarthritis and rheumatoid arthritis. The procedure fuses the bones at the wrist joint and may ease the pain caused by bone on bone contact.
Integra's Total Wrist Fusion system is designed to provide fixation of the wrist, while decreasing soft tissue irritation, and provides an optimal balance of compression and stability by combining Surfix® locking and dynamic compression technologies. Surfix® locking technology allows the surgeon to fully seat the screw in the plate prior to locking the screw in place. Integra's other products for wrist arthritis include the Universal2™ Total Wrist Implant System and the Spider TM Limited Wrist Fusion System.
"Integra is dedicated to providing surgeons with a range of choices, so they can have the right products for their patients when they need them," said Robert Paltridge, President of Integra Extremity Reconstruction. "We're very pleased that we can offer our customers an additional option for wrist arthritis."
The Integra™ Total Wrist Fusion System will be sold by Integra's Extremity Reconstruction sales organization, which focuses on lower extremity reconstruction, upper extremity reconstruction, tendon protection/augmentation, peripheral nerve repair/protection, and wound repair.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of Integra products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2009 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation Gianna Sabella, Director, Corporate Communications (609) 936-2389 email@example.com